DSGN — Design Therapeutics Share News
0.000.00%
Last trade - 00:00- $656.48m
- $449.09m
Brief: Design Therapeutics Announces Start Of Friedreich Ataxia Patient Dosing Ex-U.S. In Its Restore-Fa Phase 1/2 Multiple-Ascending Dose Trial Of Dt-216P2
Brief: Design Therapeutics Inc Files For Mixed Shelf Of Up To $300 Million - SEC Filing
Design Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Design Therapeutics Q1 Basic EPS USD -0.31
Design Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview
Brief: Design Therapeutics Q4 Basic EPS USD -0.24
Design Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Brief: Design Therapeutics Q3 Basic EPS USD -0.23
Brief: Design Therapeutics Q2 Basic EPS USD -0.21
Brief: Design Therapeutics Q1 Basic EPS USD -0.2
U.S. RESEARCH ROUNDUP- ServiceNow, Ulta Beauty, Vertex Pharmaceuticals
Design Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview
Design Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Design Therapeutics Q4 Basic EPS USD -0.21
Design Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview
Design Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Beauty Health, Design Therapeutics, Energizer Holdings
Design Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview
Brief: Design Therapeutics says Board Appointed Pratik Shah, As Co's Chief Executive Officer And Principal Financial Officer